Loblaw, a leading grocery retailer, announced a stronger profit performance in the second quarter, attributing its success to attracting budget-conscious customers to its discount chains No Frills and Maxi. The company’s pharmacy unit experienced robust sales growth, with executives highlighting the significant impact of generic GLP-1 weight loss drugs.
Based in Brampton, Ontario, Loblaw disclosed its financial results for the quarter ending June 20, revealing a revenue surpassing $15.3 billion, marking a four percent increase from the previous quarter. The profit available to common shareholders surged by five percent to $751 million.
Loblaw reported a 1.6 percent rise in same-store sales for its core retail food business, while its drug retail unit, including Shoppers Drug Mart, saw a remarkable same-store sales increase of 4.6 percent. This growth was primarily driven by a 7.5 percent rise in pharmacy and health-care services sales.
During a conference call with analysts, chief financial officer Richard Dufresne emphasized the positive impact of generic GLP-1 drugs on the company’s pharmacy performance. He noted that lower generic drug prices are being offset by higher volumes, leading to expectations of increased revenue, gross profit dollars, and gross margin rates.
Loblaw executives reported a 40 percent year-to-date increase in GLP-1 drug sales, reflecting a trend observed in the previous quarter. CEO Per Bank mentioned a shift in consumer behavior towards purchasing more frozen vegetables over fresh produce due to inflationary pressures on fresh items. Dufresne highlighted the continued success of No Frills and Maxi stores in meeting customer demand for value amid food price inflation.
Statistics Canada recently reported a 45.2 percent year-over-year surge in fresh tomato prices, prompting consumers to opt for frozen vegetables as a cost-saving measure. Loblaw’s strategic focus on value offerings has helped the company maintain its competitive edge in the market.
Amidst these developments, Loblaw’s shares traded steadily on Thursday, showing a modest year-to-date increase of approximately six percent. The company’s performance underscores its resilience in adapting to evolving consumer preferences and market dynamics.